Wall Street brokerages expect Medpace Holdings Inc (NASDAQ:MEDP) to report sales of $222.08 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Medpace’s earnings, with the highest sales estimate coming in at $225.30 million and the lowest estimate coming in at $220.41 million. Medpace reported sales of $192.12 million during the same quarter last year, which indicates a positive year over year growth rate of 15.6%. The firm is scheduled to report its next quarterly earnings report after the market closes on Monday, February 24th.

According to Zacks, analysts expect that Medpace will report full-year sales of $853.18 million for the current fiscal year, with estimates ranging from $851.49 million to $856.40 million. For the next financial year, analysts forecast that the business will post sales of $984.70 million, with estimates ranging from $967.50 million to $1.01 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Medpace.

A number of research analysts have issued reports on MEDP shares. BidaskClub upgraded shares of Medpace from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 24th. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, SunTrust Banks downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $85.00 to $87.00 in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $77.50.

In related news, CFO Jesse J. Geiger sold 14,400 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $82.00, for a total transaction of $1,180,800.00. Following the completion of the sale, the chief financial officer now directly owns 16,948 shares in the company, valued at $1,389,736. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 24.20% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Vigilant Capital Management LLC purchased a new position in shares of Medpace in the fourth quarter valued at approximately $42,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in Medpace by 53.9% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after acquiring an additional 212 shares during the last quarter. Exchange Traded Concepts LLC purchased a new position in Medpace in the fourth quarter worth approximately $80,000. Marshall Wace LLP purchased a new position in Medpace in the first quarter worth approximately $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Medpace by 32.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,848 shares of the company’s stock worth $155,000 after purchasing an additional 452 shares in the last quarter. 78.85% of the stock is owned by institutional investors.

Shares of NASDAQ MEDP traded up $0.08 during trading hours on Friday, hitting $97.86. 188,700 shares of the stock were exchanged, compared to its average volume of 178,545. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 0.07. The company has a market cap of $3.52 billion, a PE ratio of 39.46, a PEG ratio of 2.27 and a beta of 1.50. The firm has a fifty day moving average price of $88.31 and a 200-day moving average price of $81.13. Medpace has a 12 month low of $50.14 and a 12 month high of $98.70.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Recommended Story: How is diluted EPS different from basic EPS?

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.